


# Representative Life Science Deals

- Over \$8.0 Billion in Commitments to more than 430 Companies since 2003
- Total New Debt & Equity Commitments of ~\$728.7 Million YTD
- Total New Fundings of ~\$563.7 Million YTD
- Over 1,000 Co-investments with Different VC & PE Firms in the Last 14 Years
- Over 130 Companies completed IPO or M&A Events since Inception

**\$50,000,000  
Debt Commitment**

Invested in 2018  
NASDAQ: MESO



**\$75,000,000  
Debt Commitment**  
**\$2,000,000  
Equity Commitment**

Invested in 2018  
NASDAQ: TCDA



**\$30,000,000  
Debt Commitment**

Invested in 2011, 2013, 2015,  
2017  
NASDAQ: ACRX



**\$35,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: ATRS



**\$20,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: BOLD



**\$55,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: AXON




**\$30,000,000  
Debt Commitment**

Invested in 2016, 2017  
NASDAQ: BLCM




**\$25,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: CCXI




**\$30,000,000  
Debt Commitment**

Invested in 2017



**\$40,000,000  
Debt Commitment**

Invested in 2017  
NYSE: MYOV



**\$30,000,000  
Debt Commitment**

Invested in 2017



**\$15,000,000  
Debt Commitment**  
**\$1,000,000  
Equity Commitment**

Invested in 2014, 2015,  
2016, 2017  
NASDAQ: QTRX



\$35,000,000  
**Debt Commitment**

Invested in 2018



\$40,000,000  
**Debt Commitment**

Invested in 2018  
NASDAQ: TRXC



\$30,000,000  
**Debt Commitment**  
\$20,000,000  
**Prior Debt Commitment**

Invested in 2011, 2012, 2017  
NASDAQ: CNCE



\$60,000,000  
**Debt Commitment**  
\$1,000,000  
**Equity Commitment**

Invested in 2014, 2015, 2016, 2017  
NASDAQ: PRTK



\$20,000,000  
**Debt Commitment**

Invested in 2017



\$45,000,000  
**Debt Commitment**

Invested in 2014, 2015, 2016  
NASDAQ: ALIM



\$55,000,000  
**Debt Commitment**  
\$1,000,000  
**Equity Commitment**

Invested in 2014, 2015  
Acquired by Jazz Pharma in 2016



\$60,000,000  
**Debt Commitment**

Invested in 2016  
NASDAQ: SRNE



\$15,000,000  
**Debt Commitment**

Invested in 2014, 2015  
Acquired by Jazz Pharma in 2016



\$40,000,000  
**Debt Commitment**  
\$550,000  
**Equity Commitment**

Invested in 2014, 2015  
NASDAQ: DVAX



\$30,000,000  
**Debt Commitment**  
\$2,000,000  
**Prior Debt Commitment**

Invested in 2014, 2015  
NASDAQ: MLNT



\$25,000,000  
**Debt Commitment**  
\$55,000,000  
**Prior Debt Commitment**

Invested in 2005, 2007, 2012, 2015  
NASDAQ: MACK



\$8,500,000  
**Debt Commitment**  
\$2,500,000  
**Equity Commitment**

Invested in 2008, 2010,  
2012, 2015



\$20,000,000  
**Debt Commitment**

Invested in 2013, 2014  
NASDAQ: QURE



\$45,000,000  
**Debt Commitment**

Invested in 2013  
Acquired by Pfizer in 2016



\$22,000,000  
**Debt Commitment**

Invested in 2011  
NASDAQ: RVNC

## Boston Office

### R. Bryan Jadot

Sr. Managing Director  
617.314.9981  
bjadot@htgc.com

### Kristen Kosofsky

Sr. Managing Director  
617.851.5416  
kkosofsky@htgc.com

### Janice Bourque

Managing Director  
617.314.9992  
jbourque@htgc.com

## Palo Alto Office

### Nimesh Shah

Managing Director  
650.433.5548  
nshah@htgc.com

### Himani Bhalla

Principal  
650.433.5581  
hbhalla@htgc.com

## San Diego Office

### Lake McGuire

Managing Director  
517.304.0382  
lmcguire@htgc.com

## New York Office

### Anup Arora

Managing Director  
212.774.3612  
aarora@htgc.com